<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04243798</url>
  </required_header>
  <id_info>
    <org_study_id>54909</org_study_id>
    <nct_id>NCT04243798</nct_id>
  </id_info>
  <brief_title>Establishing a Dose-response Relationship With Accelerated Transcranial Magnetic Stimulation</brief_title>
  <official_title>Utilizing Changes in Human Brain Connectivity to Establish a Dose-response Relationship Involved in the Therapeutic Actions of Prefrontal Brain Stimulation on Depression Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial
      magnetic stimulation device for treatment-resistant depression. In a double-blind,
      randomized, sham-controlled fashion, half the participants will receive accelerated
      theta-burst stimulation while half will receive sham treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Repetitive transcranial magnetic stimulation (rTMS) is an established therapy for
      treatment-resistant depression. The approved method for treatment is 10Hz stimulation for 40
      min over the left dorsolateral prefrontal cortex (L-DLPFC). This methodology has been
      effective in real world situations. The limitations of this approach include the duration of
      the treatment (approximately 40 minutes per treatment session, 5 days per week, for 4-8
      weeks). Recently, we have pursued modifying the treatment parameters to reduce treatment
      times with an accelerated treatment paradigm with great preliminary success. This study aims
      to further study our accelerated protocol and examine changes in neuroimaging biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in Montgomery-Ã…sberg Depression Rating Scale (MADRS) score from pre-treatment to 1-month post-treatment.</measure>
    <time_frame>Baseline (Pretreatment), 1-month posttreatment</time_frame>
    <description>A ten item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change in the Hamilton Rating Scale for Depression (HAMD-17)</measure>
    <time_frame>4 weeks posttreatment</time_frame>
    <description>A provider administered questionnaire used to assess remission and recovery from depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in the Hamilton Rating Scale for Depression (HAM-6)</measure>
    <time_frame>Follow-up every 2 weeks for 6 months by telephone</time_frame>
    <description>A 6 item questionnaire used to score the severity of depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in the Hamilton Rating Scale for Depression (HAMD-17)</measure>
    <time_frame>Baseline (Pretreatment), immediately posttreatment, 2 weeks posttreatment</time_frame>
    <description>A provider administered questionnaire used to assess remission and recovery from depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline functional connectivity to immediate post-treatment</measure>
    <time_frame>Baseline (Pretreatment), immediately post-treatment</time_frame>
    <description>Functional connectivity of subcallosal cingulate to the default mode network and within the default mode network.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline functional connectivity to 1-month post-treatment</measure>
    <time_frame>Baseline (Pretreatment), 1-month post-treatment</time_frame>
    <description>We will assess functional connectivity as seen on resting state fMRI, between the subcallosal cingulate to the default mode network and within the default mode network.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline functional connectivity to each day of treatment</measure>
    <time_frame>Baseline (Pretreatment), daily during treatment</time_frame>
    <description>We will assess functional connectivity as seen on resting state fMRI, between the subcallosal cingulate to the default mode network and within the default mode network, and compare functional connectivity between baseline and treatment day 1, baseline and treatment day 2, baseline and treatment day 3, baseline and treatment day 4, and baseline and treatment day 5 to see if and when changes occur.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in the Immediate Mood Scaler (IMS)</measure>
    <time_frame>Baseline, daily during treatment, immediately post-treatment, and 1-month following treatment</time_frame>
    <description>A 12 item questionnaire used to assess mood</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <arm_group>
    <arm_group_label>Active TBS-DLPFC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The active group will receive theta-burst TMS stimulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham TBS-DLPFC</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The sham group will receive sham theta-burst TMS stimulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active TBS-DLPFC</intervention_name>
    <description>Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing Nexstim's eField neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).
Stimulation will be delivered to the L-DLPFC using a Nexstim TMS device.</description>
    <arm_group_label>Active TBS-DLPFC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham TBS-DLPFC</intervention_name>
    <description>The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.</description>
    <arm_group_label>Sham TBS-DLPFC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Open label TBS-DLPFC</intervention_name>
    <description>All patients will have the option to receive active, open label aTBS treatment after the 1-month mark, following the blinded phase.
Stimulation will be delivered to the L-DLPFC using a Nexstim TMS device.</description>
    <arm_group_label>Active TBS-DLPFC</arm_group_label>
    <arm_group_label>Sham TBS-DLPFC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 22 to 75 years of age.

          -  Able to provide informed consent.

          -  Diagnosed with Major Depressive Disorder (MDD) and currently experiencing a Major
             Depressive Episode (MDE).

          -  Must have a stable psychiatrist during study enrollment who confirms MDD/current MDE

          -  Must be on a stable anti-depressant regimen for 6 weeks prior to study enrollment and
             agree to continue this regimen during study period

          -  Participants must qualify as &quot;Moderately Treatment Refractory&quot; or &quot;High Treatment
             Refractory&quot; using the Maudsley staging method.

          -  Meet the threshold on the total HAMD17 score of &gt;/=20 at both screening and baseline
             visits (Day -5/-14 and Day 0).

          -  In good general health, as ascertained by medical history.

          -  If female, a status of non-childbearing potential or use of an acceptable form of
             birth control. The form of birth control will be documented at screening and baseline.

          -  Agree to and able to have at least 6 fMRI scan sessions as well as 5 days of SAINT
             sessions per day (for each course of SAINT).

        Exclusion Criteria:

          -  Female of childbearing potential who is not willing to use one of the specified forms
             of birth control during the study.

          -  Female that is pregnant or breastfeeding.

          -  Female with a positive pregnancy test at participation.

          -  History of epilepsy.

          -  History of rTMS exposure.

          -  History of any implanted device or psychosurgery for depression.

          -  History of shrapnel or metal in the head or skull.

          -  History of OCD.

          -  History of autism spectrum disorder.

          -  History of intractable migraine

          -  History of independent sleep disorder.

          -  â€¢ Any current or past history of any physical condition which in the investigator's
             opinion might put the subject at risk of interfere with study results interpretation

          -  Active substance abuse (within the past 6 months) or intoxication verified by
             toxicology screen - of cocaine, amphetamines, benzodiazepines, alcohol

          -  Cognitive impairment (including dementia)

          -  Current severe insomnia (must sleep a minimum of 4 hours the night before stimulation)

          -  Current mania or psychosis

          -  Showing symptoms of withdrawal from alcohol or benzodiazepines

          -  Parkinsonism or other movement d/o determined by PI to interfere with treatment

          -  Any other indication the PI feels would compromise data

          -  Active suicidal ideation or a suicide attempt with in the past 90 days

          -  A diagnosis of bipolar type 1 or 2

          -  Any history of myocardial infarction, CABG, CHF, or other cardiac history deemed by
             the PI to interfere with the study

          -  The presence of diagnosis of primary generalized anxiety disorder or personality
             disorder

          -  Under 22 years or age or over 75 years of age at time of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nolan Williams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Romina Nejad, MSc</last_name>
    <phone>650-497-3933</phone>
    <email>rnejad@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole Odenwald, MA</last_name>
    <phone>650-736-2233</phone>
    <email>nicole.odenwald@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Psychiatry and Behavioral Sciences, Stanford School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Romina Nejad, MSc</last_name>
      <phone>650-497-3933</phone>
      <email>rnejad@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Nolan Williams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>George MS, Lisanby SH, Avery D, McDonald WM, Durkalski V, Pavlicova M, Anderson B, Nahas Z, Bulow P, Zarkowski P, Holtzheimer PE 3rd, Schwartz T, Sackeim HA. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry. 2010 May;67(5):507-16. doi: 10.1001/archgenpsychiatry.2010.46.</citation>
    <PMID>20439832</PMID>
  </reference>
  <reference>
    <citation>George MS, Wassermann EM, Williams WA, Callahan A, Ketter TA, Basser P, Hallett M, Post RM. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuroreport. 1995 Oct 2;6(14):1853-6.</citation>
    <PMID>8547583</PMID>
  </reference>
  <reference>
    <citation>Pascual-Leone A, Rubio B, PallardÃ³ F, CatalÃ¡ MD. Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet. 1996 Jul 27;348(9022):233-7.</citation>
    <PMID>8684201</PMID>
  </reference>
  <reference>
    <citation>Chung SW, Hill AT, Rogasch NC, Hoy KE, Fitzgerald PB. Use of theta-burst stimulation in changing excitability of motor cortex: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2016 Apr;63:43-64. doi: 10.1016/j.neubiorev.2016.01.008. Epub 2016 Feb 3. Review.</citation>
    <PMID>26850210</PMID>
  </reference>
  <reference>
    <citation>JeliÄ‡ MB, MilanoviÄ‡ SD, FilipoviÄ‡ SR. Differential effects of facilitatory and inhibitory theta burst stimulation of the primary motor cortex on motor learning. Clin Neurophysiol. 2015 May;126(5):1016-23. doi: 10.1016/j.clinph.2014.09.003. Epub 2014 Sep 16.</citation>
    <PMID>25281475</PMID>
  </reference>
  <reference>
    <citation>Chung SW, Hoy KE, Fitzgerald PB. Theta-burst stimulation: a new form of TMS treatment for depression? Depress Anxiety. 2015 Mar;32(3):182-92. doi: 10.1002/da.22335. Epub 2014 Nov 28. Review.</citation>
    <PMID>25450537</PMID>
  </reference>
  <reference>
    <citation>Plewnia C, Pasqualetti P, GroÃŸe S, Schlipf S, Wasserka B, Zwissler B, Fallgatter A. Treatment of major depression with bilateral theta burst stimulation: a randomized controlled pilot trial. J Affect Disord. 2014 Mar;156:219-23. doi: 10.1016/j.jad.2013.12.025. Epub 2013 Dec 28.</citation>
    <PMID>24411682</PMID>
  </reference>
  <reference>
    <citation>Prasser J, Schecklmann M, Poeppl TB, Frank E, Kreuzer PM, Hajak G, Rupprecht R, Landgrebe M, Langguth B. Bilateral prefrontal rTMS and theta burst TMS as an add-on treatment for depression: a randomized placebo controlled trial. World J Biol Psychiatry. 2015 Jan;16(1):57-65. doi: 10.3109/15622975.2014.964768. Epub 2014 Nov 28.</citation>
    <PMID>25430687</PMID>
  </reference>
  <reference>
    <citation>Daskalakis ZJ. Theta-burst transcranial magnetic stimulation in depression: when less may be more. Brain. 2014 Jul;137(Pt 7):1860-2. doi: 10.1093/brain/awu123. Epub 2014 May 15.</citation>
    <PMID>24833712</PMID>
  </reference>
  <reference>
    <citation>Thut G, Pascual-Leone A. A review of combined TMS-EEG studies to characterize lasting effects of repetitive TMS and assess their usefulness in cognitive and clinical neuroscience. Brain Topogr. 2010 Jan;22(4):219-32. doi: 10.1007/s10548-009-0115-4. Epub 2009 Oct 28. Review.</citation>
    <PMID>19862614</PMID>
  </reference>
  <reference>
    <citation>Holtzheimer PE 3rd, McDonald WM, Mufti M, Kelley ME, Quinn S, Corso G, Epstein CM. Accelerated repetitive transcranial magnetic stimulation for treatment-resistant depression. Depress Anxiety. 2010 Oct;27(10):960-3. doi: 10.1002/da.20731.</citation>
    <PMID>20734360</PMID>
  </reference>
  <reference>
    <citation>Fung PK, Robinson PA. Neural field theory of synaptic metaplasticity with applications to theta burst stimulation. J Theor Biol. 2014 Jan 7;340:164-76. doi: 10.1016/j.jtbi.2013.09.021. Epub 2013 Sep 21.</citation>
    <PMID>24060620</PMID>
  </reference>
  <reference>
    <citation>Biswal B, Yetkin FZ, Haughton VM, Hyde JS. Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. Magn Reson Med. 1995 Oct;34(4):537-41.</citation>
    <PMID>8524021</PMID>
  </reference>
  <reference>
    <citation>Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):253-8. Epub 2002 Dec 27.</citation>
    <PMID>12506194</PMID>
  </reference>
  <reference>
    <citation>Fox MD, Snyder AZ, Vincent JL, Corbetta M, Van Essen DC, Raichle ME. The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9673-8. Epub 2005 Jun 23.</citation>
    <PMID>15976020</PMID>
  </reference>
  <reference>
    <citation>Greicius MD, Supekar K, Menon V, Dougherty RF. Resting-state functional connectivity reflects structural connectivity in the default mode network. Cereb Cortex. 2009 Jan;19(1):72-8. doi: 10.1093/cercor/bhn059. Epub 2008 Apr 9.</citation>
    <PMID>18403396</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 25, 2020</study_first_submitted>
  <study_first_submitted_qc>January 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>February 23, 2020</last_update_submitted>
  <last_update_submitted_qc>February 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Nolan R</investigator_full_name>
    <investigator_title>Instructor of Psychiatry &amp; Behavioral Sciences, Director of the Brain Stimulation Laboratory at Stanford University School of Medicine, Stanford University</investigator_title>
  </responsible_party>
  <keyword>transcranial magnetic stimulation</keyword>
  <keyword>theta burst</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

